Abstract:BACKGROUND: Published data have suggested a critical role for microRNA (miRNA) expression in chordoma progression. However, most of these studies focus on single miRNA and no multi-miRNA prognostic signature has been currently established for chordoma. In this study, we sought to develop and validate a 6-miRNA risk score (miRscore) model for survival prediction.METHODS: Medline, Embase, and Google scholar searches (from inception to July 20, 2018) were conducted to identify candidate miRNAs with prognostic value as per predefined criteria. Quantitative RT-PCR was used to measure miRNA levels in 114 spinal chordoma (54 in the training and 60 in the validation cohort) and 20 control specimens. Subsequently, the miRscore was built based on miRNAs data.RESULTS: Literature searches identified six prognostic miRNAs (miR-574-3p, miR-1237-3p, miR-140-3p, miR-1, miR-155, and miR-1290) with differential expression in tumor tissues. Bioinformatical analysis revealed an important regulatory role for miR-574-3p/EGFR signaling in chordoma and showed that the target genes of these prognostic miRNAs were mainly enriched in transcription regulation, protein binding and cancer-related pathways. In both cohorts, the miRscore was associated with surrounding muscle invasion by tumor and/or other aggressive features. The miRscore model well predicted local recurrence-free survival and overall survival, which remained after adjusting for other relevant covariates. Further time-dependent receiver operating characteristics analysis in the two cohorts found that the miRscore classifier had stronger prognostic power than known clinical predictors and improved the ability of Enneking staging to predict outcomes. Importantly, recursive-partitioning analysis of both samples combined separated patients into four prognostically distinct risk subgroups for recurrence and survival (both <i>P</i> < 0.001).CONCLUSIONS: These data suggest the miRscore as a useful prognostic stratification tool in spinal chordoma and may represent an important step toward future personalized treatment of patients.

Identification Of Mir-140-3p As A Marker Associated With Poor Prognosis In Spinal Chordoma

Reduced Expression of Mirna-1237-3p Associated with Poor Survival of Spinal Chordoma Patients

Clinicopathologic Implications of CD8 + /foxp3 + Ratio and Mir-574-3p/pd-l1 Axis in Spinal Chordoma Patients

Development and Validation of a 6-miRNA Prognostic Signature in Spinal Chordoma

Expression Characteristics and Prognosissignificance of Mirna-181A in Acute Myeloid Leukemia with Normal Karyotype

Low expression of H3K27me3 is associated with poor prognosis in conventional chordoma

Downregulation of Mir-138 Predicts Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma.

Integrated Mirna-Mrna Analysis Revealing The Potential Roles Of Mirnas In Chordomas

LncRNA NONHSAT114552 Sponges miR-320d to Promote Proliferation and Invasion of Chordoma Through Upregulating NRP1

Prognostic Biomarkers in Spinal Chordoma: A Systematic Review

Differential Proteomic Profiling of Chordomas and Analysis of Prognostic Factors

Function and regulation of miR-186-5p, miR-125b-5p and miR-1260a in chordoma

Preserved Mir-361-3p Expression is an Independent Prognostic Indicator of Favorable Survival in Cervical Cancer

Long non-coding RNA LINC00525 interacts with miR-31–5p and miR-125a-5p to act as an oncogenic molecule in spinal chordoma

MicroRNA‐1224 inhibits cell proliferation by downregulating CBX3 expression in chordoma

Mir-31-5p-dmd Axis As a Novel Biomarker for Predicting the Development and Prognosis of Sporadic Early-Onset Colorectal Cancer

Clinical Features and Prognostic Factors of Patients with Chordoma in the Spine: a Retrospective Analysis of 153 Patients in a Single Center.

Inhibition of Mir-140-3p or Mir-155-5p by Antagomir Treatment Sensitize Chordoma Cells to Chemotherapy Drug Treatment by Increasing PTEN Expression

miR-16-5p inhibits chordoma cell proliferation, invasion and metastasis by targeting Smad3

Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.

Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore As an Independent Favorable Prognostic Factor.